The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4

被引:117
作者
Bursen, Adelheid [1 ]
Schwabe, Karen [1 ]
Ruester, Brigitte [2 ]
Henschler, Reinhard [2 ]
Ruthardt, Martin [3 ]
Dingermann, Theo [1 ]
Marschalek, Rolf [1 ]
机构
[1] Goethe Univ Frankfurt, Inst Pharmaceut Biol, Bioctr, ZAFES,DCAL, D-60438 Frankfurt, Germany
[2] German Red Cross, Ctr Blood Transfus, Inst Transfus Med & Immunohematol, Frankfurt, Germany
[3] Goethe Univ Frankfurt, Dept Internal Med 2, D-60438 Frankfurt, Germany
关键词
MYELOID PROGENITORS; ACUTE LEUKEMIAS; CHROMOSOMAL TRANSLOCATIONS; GENE-TRANSFER; CELL-LINE; HRX-ENL; MLL-ELL; TRANSFORMATION; IMMORTALIZATION; AF4;
D O I
10.1182/blood-2009-06-229542
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The chromosomal translocation t(4;11)(q21;q23) is the most frequent genetic aberration of the human MLL gene, resulting in high-risk acute lymphoblastic leukemia (ALL). To elucidate the leukemogenic potential of the fusion proteins MLL.AF4 and AF4.MLL, Lin(-)/Sca1(+) purified cells (LSPCs) were retrovirally transduced with either both fusion genes or with MLL.AF4 or AF4.MLL alone. Recipients of AF4.MLL- or double-transduced LSPCs developed pro-B ALL, B/T biphenotypic acute leukemia, or mixed lineage leukemia. Transplantation of MLL.AF4- or mock-transduced LSPCs did not result in disease development during an observation period of 13 months. These findings indicate that the expression of the AF4.MLL fusion protein is capable of inducing acute lymphoblastic leukemia even in the absence of the MLL.AF4 fusion protein. In view of recent findings, these results may imply that t(4; 11) leukemia is based on 2 oncoproteins, providing an explanation for the very early onset of disease in humans. (Blood. 2010; 115(17): 3570-3579)
引用
收藏
页码:3570 / 3579
页数:10
相关论文
共 38 条
[1]   Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9 [J].
Ayton, PM ;
Cleary, ML .
GENES & DEVELOPMENT, 2003, 17 (18) :2298-2307
[2]   The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling [J].
Bitoun, Emmanuelle ;
Oliver, Peter L. ;
Davies, Kay E. .
HUMAN MOLECULAR GENETICS, 2007, 16 (01) :92-106
[3]   Interaction of AF4 wild-type and AF4. MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology? [J].
Bursen, A ;
Moritz, S ;
Gaussmann, A ;
Moritz, S ;
Dingermann, T ;
Marschalek, R .
ONCOGENE, 2004, 23 (37) :6237-6249
[4]   Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein [J].
Caslini, C ;
Serna, A ;
Rossi, V ;
Introna, M ;
Biondi, A .
LEUKEMIA, 2004, 18 (06) :1064-1071
[5]   A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy [J].
Chen, Weili ;
Li, Quanzhi ;
Hudson, Wendy A. ;
Kumar, Ashish ;
Kirchhof, Nicole ;
Kersey, John H. .
BLOOD, 2006, 108 (02) :669-677
[6]   ONCOGENIC CONVERSION OF TRANSCRIPTION FACTORS BY CHROMOSOMAL TRANSLOCATIONS [J].
CLEARY, ML .
CELL, 1991, 66 (04) :619-622
[7]   An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes [J].
Corral, J ;
Lavenir, I ;
Impey, H ;
Warren, AJ ;
Forster, A ;
Larson, TA ;
Bell, S ;
McKenzie, ANJ ;
King, G ;
Rabbitts, TH .
CELL, 1996, 85 (06) :853-861
[8]   The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10 [J].
DiMartino, JF ;
Ayton, PM ;
Chen, EH ;
Naftzger, CC ;
Young, BD ;
Cleary, ML .
BLOOD, 2002, 99 (10) :3780-3785
[9]   A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL [J].
DiMartino, JF ;
Miller, T ;
Ayton, PM ;
Landewe, T ;
Hess, JL ;
Cleary, ML ;
Shilatifard, A .
BLOOD, 2000, 96 (12) :3887-3893
[10]   Physical association and coordinate function of the H3K4 methyltransferase MLL1 and the H4K16 acetyltransferase MOF [J].
Dou, YL ;
Milne, TA ;
Tackett, AJ ;
Smith, ER ;
Fukuda, A ;
Wysocka, J ;
Allis, CD ;
Chait, BT ;
Hess, JL ;
Roeder, RG .
CELL, 2005, 121 (06) :873-885